comparemela.com

Latest Breaking News On - Advanced solid - Page 5 : comparemela.com

Preliminary Ongoing Results with CYT-0851 in Combination with Capecitabine or Gemcitabine in Advanced Solid Tumors Show Early Clinical Activity and Generally Well Tolerated Safety Profile

- CYT-0851 has demonstrated early activity in combination with capecitabine or gemcitabine in advanced solid tumors and a generally well tolerated safety profile in a heavily pretreated population of. | June 3, 2023

United statesMarkus renschlerExchange commissionAmerican society of clinical oncologyCyteir therapeutics incCyteir therapeuticsMonocarboxylate transporterAdvanced solidClinical oncologyChief executive officerAnnual reportNc stock exchangePress releaseOpulation cyt us23284p1030

Exelixis Announces First Quarter 2023 Financial Results and Provides Corporate Update

- Total Revenues of $408.8 million, Cabozantinib Franchise U.S. Net Product Revenues of $363.4 million - - GAAP Diluted EPS of $0.12, Non-GAAP Diluted EPS of $0.16 - - Conference Call and Webcast. | May 9, 2023

United statesMichaelm morrisseySairopabv sairopaPharmaceuticals incExchange commissionDistrict courtMillion share repurchase programTakeda pharmaceutical companyDrug administrationDistrict of delaware the courtUs district courtDelaware district courtInternational metastatic renal cell carcinoma database consortiumAmerican society of clinical oncologyExelixis incChief executive officer

Innate Pharma SA: Innate Pharma Reports Full Year 2022(1) Financial Results and Business Update

Sanofi collaboration for Natural Killer cell engager therapeutics expanded to B7-H3 ANKETprogram and two additional targets, with €25 million payment Encouraging preliminary TELLOMAK Phase

United statesArthur rouillMondher mahjoubiHenry wheelerPatrick langloisSally bennettInstitut paoli calmettesHart scott rodinoNovo nordiskFrench financial markets authority autoritCorporate affairsAmerican society hematology annual meetingOncology io annual congressEuropean unionLymphoma study associationAudit committee

Nectin Therapeutics Raises $25M for Immuno-Oncology Therapies

- Nectin Therapeutics Ltd., (Nectin) a biotechnology company has extended its Series A financing to over $25M for immuno-oncology therapies

United statesPini tsukermanMoon fundCancer focus fundNectin therapeutics ltdNectin therapeutics raisesShould knowPeregrine venturesAntibody drug conjugatesHuman phaseAdvanced solidCancer centerSarina phia paulAssociate professorInvestigational cancer therapeutics

Grey Wolf Therapeutics Announces Clinical Supply Agreement with Regeneron for Trial Evaluating GRWD5769 in Combination with Libtayo® (cemiplimab)

/PRNewswire/ Grey Wolf Therapeutics, a biotechnology company focused on generating entirely novel anti-tumour immune responses through targeted cancer.

United kingdomRegeneron libtayoPeter joyceAdvanced solidGrey wolf therapeuticsGrey wolfWolf therapeuticsStrategic partnersHealth care amp hospitalsMedical pharmaceuticalsClinical trials amp medical discoveries

vimarsana © 2020. All Rights Reserved.